12:00 AM
 | 
Dec 03, 2012
 |  BC Week In Review  |  Company News  |  Deals

Inovio, University of Pennsylvania deal

The partners expanded for a third time a 2007 deal to include exclusive, worldwide rights to the university's preclinical synthetic vaccines against cancers with mutations in the Wilms tumor 1 (WT1) gene; infectious diseases, including Clostridium...

Read the full 167 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >